Latest Earnings Results: Q2 '26
Estimated EPS
-$0.50
Reported EPS
-$0.52
Surprise
-4%
Estimated Rev
$6.35M
Reported Rev
$7.9M
Surprise
+24.36%
BioStem Technologies reported Q2 2026 net revenue of $7.9M, a 28% YoY decrease, driven by CMS reimbursement changes that reduced physician office revenue by 90% compared to Q2 2025.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.43 | -- | -- | N/A |
Q2 '26 | -$0.50 | -$0.52 | -4.00% | MISSED |
Q1 '26 | -$0.28 | -$0.52 | -85.71% | MISSED |
Q4 '25 | $0.02 | -$0.67 | -3450.00% | MISSED |
Q3 '25 | $0.00 | $0.03 | 100.00% | BEAT |